Celldex Therapeutics, Inc.
CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receā¦ read more
Healthcare
Biotechnology
38 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$26.47
Price-2.43%
-$0.66
1Y
Price
Market Cap
$1.758b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-25534.0%
EBITDA Margin-21030.8%
Net Profit Margin-26270.5%
Free Cash Flow MarginRevenue
$5.791m
-11.8%
1y CAGR+43.6%
3y CAGR+23.4%
5y CAGREarnings
-$199.609m
-2.4%
1y CAGR-30.6%
3y CAGR-27.4%
5y CAGREPS
-$3.01
+2.4%
1y CAGR-22.9%
3y CAGR-12.5%
5y CAGRBook Value
$655.406m
$692.407m
Assets$37.001m
Liabilities$3.031m
DebtDebt to Assets
0.4%
-
Debt to EBITDAFree Cash Flow
-$187.056m
-10.8%
1y CAGR-28.0%
3y CAGR-33.0%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company